 |
|
|
| |
From Clinical Trials to Real-World Evidence: Similar Virologic Cure Rates and Safety Outcomes Following Treatment With Glecaprevir/Pibrentasvir Among Patients With Chronic Hepatitis C Virus Infection and Recent Drug Use
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Alessio Aghemo1, Francesco Negro2, Michael Gschwantler3, Tarik Asselah4, Mark Bondin5, Eric Crown5, Miki Mancine5, Zhenzhen Zhang5, Robert Flisiak6, Jason Grebely7, Norbert Bräu8,9, Richard Sterling10
1Humanitas University and Research Hospital, Rozzano, Italy; 2University of Geneva, Geneva, Switzerland; 3Department of Internal Medicine IV, Wilhelminenspital, and Sigmund Freud University, Vienna, Austria; 4Hopital Beaujon, Paris University & INSERM UMR 1149, Clichy, France; 5AbbVie Inc., North Chicago, Illinois, United States; 6Department of Infectious Diseases and Hepatology, Medical University of Biaystok, Biaystok, Poland; 7The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia; 8James J Peters Veterans Affairs Medical Center, Infectious Diseases Section, Bronx, New York, United States; 9Department of Medicine, Division of Infectious Diseases & Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, United States; 10Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, Virginia, United States
|
| |
|
|
|
|
|
